- Home
- STEW vs MESO Comparison
STEW vs MESO Comparison
Compare STEW & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEW | MESO |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | STEW | MESO |
|---|---|---|
| Price | $17.89 | $18.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | 84.5K | ★ 191.8K |
| Earning Date | 01-01-0001 | 08-28-2025 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | N/A | ★ $17,198,000.00 |
| Revenue This Year | N/A | $465.44 |
| Revenue Next Year | N/A | $75.37 |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $11.97 | $9.61 |
| 52 Week High | $14.94 | $22.00 |
Technical Indicators
Market Signals| Indicator | STEW | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 69.40 |
| Support Level | $17.96 | $16.43 |
| Resistance Level | $18.20 | $17.65 |
| Average True Range (ATR) | 0.19 | 0.66 |
| MACD | -0.01 | 0.35 |
| Stochastic Oscillator | 42.47 | 92.34 |
Price Performance
Historical ComparisonAbout STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.